FDA given new powers over data reporting to national clinical trials registry

BMJ 2012; 345 doi: http://dx.doi.org/10.1136/bmj.e6629 (Published 2 October 2012)
Cite this as: BMJ 2012;345:e6629

Get access to this article and all of bmj.com for the next 14 days

Sign up for a 14 day free trial today

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Bob Roehr
  1. 1Washington, DC

The US Food and Drug Administration (FDA) has been given the authority to monitor and enforce the reporting of required data to the national clinical trials registry (ClinicalTrials.gov).

Authority for the registry previously rested with the Secretary of Health but was transferred to the FDA on 26 September.1 The move is seen as a streamlining or rationalization of administrative responsibilities and will probably result in enhanced accountability.

The National Institute for Health’s (NIH) National Library of Medicine operates the ClinicalTrials.gov database. A 2007 change in the law required that “basic results” for certain clinical trials, including those submitted to the FDA for …

Get access to this article and all of bmj.com for the next 14 days

Sign up for a 14 day free trial today

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

Article access

Article access for 1 day

Purchase this article for £20 $30 €32*

The PDF version can be downloaded as your personal record

* Prices do not include VAT

THIS WEEK'S POLL